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Abstract
Inflammatory bowel diseases (IBD) present a broad inflammatory cascade that 
is sometimes difficult to control. Patients with ulcerative colitis (UC) and Crohn’s 
disease (CD) are exposed to intense and harmful effects that compromise their 
quality of life. There is a constant need for new classes of drugs that act on differ-
ent fronts of inflammation control. Initially, biologics revolutionized inflamma-
tory bowel disease treatment. Anti-tumor necrosis factor (anti-TNF) agents and 
infliximab, followed by adalimumab and certolizumab pegol, have been proven 
to induce clinical and endoscopic remission. However, some patients are primary 
nonresponders, and a significant proportion of initial responders lose response 
throughout the treatment. The emergence of new therapies, such as anti-integrins, 
anti-interleukins, and inhibitors of Janus kinase (JAK), can become an alternative 
option for patients with previous therapeutic failures, besides offering greater 
safety than other biological therapies up to now. Among anti-integrins, vedoli-
zumab is the drug with proven efficacy in both induction and maintenance of 
remission and has local and selective action in the intestine. Ustekinumab repre-
sents the group of anti-interleukins, acting to control interleukin-12 (IL12) and 
interleukin-23 (IL23). JAK inhibitors (tofacitinib) act on intracellular inflammatory 
mediators and have the advantage of being orally administered.
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1. Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the main inflammatory 
bowel diseases (IBD) [1]. Inappropriate inflammatory response is multifacto-
rial and involves environmental, genetic, immune-mediated, and gut microbial 
 factors [2].
IBDs were previously more prevalent in North America, Europe, and Oceania, 
but since 1990 the incidence rate is stable or decreasing in those areas. In contrast, 
increasing incidence was observed in developing regions, such as Latin and South 
America, Asia, and Africa, making it a rising global disease [3].
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For years, the therapeutic management of IBD has been restricted to local action 
medications with mild anti-inflammatory power, such as amino salicylates and 
corticosteroids. Adverse effects of prolonged use of corticosteroids include infec-
tions, diabetes, osteoporosis, cataracts, metabolic syndrome, and esthetic changes 
that further raise morbidity and mortality [4].
Immunomodulators initially used in rheumatologic conditions have also been 
applied in IBD treatment. Thiopurines (azathioprine and 6-mercaptopurines) and 
methotrexate were widely used against both UC and CD, but these medications 
alone failed to induce and maintain clinical and endoscopic remission in a signifi-
cant percentage of cases. Failure to control the disease increases the risk of com-
plications, like strictures, abscesses, fistulas, and the need for surgical approaches. 
Additionally, worse quality of life and an increase in clinical complications like 
anemia and malnutrition [5] may occur.
The therapeutic revolution of IBDs began with biological therapy containing 
anti-tumor necrosis factor (anti-TNF) agents such as infliximab, which was widely 
used in the management of rheumatologic, dermatological, and inflammatory 
bowel diseases. Subsequently, other drugs of the same class emerged, such as 
adalimumab, a fully human monoclonal antibody, and certolizumab, which does 
not have the Fc portion, making it less immunogenic [5].
Anti-TNF treatment (alone or in combination with immunomodulators) can 
induce clinical and endoscopic remission. However, only 10–30% will have a 
primary no-response, and over 50% will, after an initial response, have a secondary 
loss [6].
New classes of immunobiological therapies are available to treat patients with 
loss of response to anti-TNF treatment, since the response to a second anti-TNF is 
low [4, 5]. Integrins and interleukins are the main targets of the available drugs to 
treat IBD. They act on receptors of cells involved in the inflammatory process and 
on proinflammatory cytokines, respectively. Furthermore, the intracellular inhibi-
tion of kinases by JAK inhibitors acts on intracellular inflammatory mediators. Each 
of these action pathways will be detailed in this chapter.
2. Anti-integrins and anti-interleukin 12/23p40
2.1 Anti-integrins
Integrins are cell surface glycoprotein receptors that play a role in leukocyte 
adhesion, signaling, proliferation, and migration [7]. Migration of circulating leu-
cocytes from blood to intestinal tissue is a key step for intestinal inflammation. α4β7 
integrin expressed on the surface of the leukocyte binds to mucosal addressin cell 
adhesion molecule-1 (MAdCAM-1) expressed on endothelial cells. Anti-integrin 
blocks the action of integrins, inhibiting leukocyte trafficking from the systemic 
circulation to the gastrointestinal endothelial cells [8].
Natalizumab is a chimeric recombinant human IgG4 antibody that blocks 
the α4 subunits in α4β7 and α4β1 integrins on leukocytes, inhibits binding to 
vascular cell adhesion molecule 1 (VCAM-1), and decreases inflammatory cells 
in affected gastrointestinal tissue, contributing to induction and maintenance 
of remission in CD [9]. Natalizumab also blocks lymphocyte infiltration in the 
central nervous system and is also approved for multiple sclerosis treatment 
[10]. However, association with progressive multifocal leukoencephalopathy 
(PML), a rare disabling and potentially fatal neurological syndrome caused by 
reactivation of the John Cunningham virus (JCV), has limited its use in treating 
CD patients [11].
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Etrolizumab is a humanized IgG1 monoclonal antibody against the β7 subunit 
of the α4β7 and αEβ7 integrins that blocks binding to MAdCAM-1 and E-cadherin, 
respectively [12]. Still under study, it is not part of the IBD therapeutic arsenal, and 
studies failed to demonstrate an advantage when compared to placebo [13].
Vedolizumab is an anti-integrin currently used to treat IBD. It is a humanized 
monoclonal antibody composed of two light chains of kappa subclass and two 
heavy chains linked by two disulfide bridges, which form an immunoglobulin 
that targets α4β7 integrin, selectively blocking gut lymphocyte trafficking 
[14]. Its inhibitory effect on T-lymphocyte recruitment is reversible with its 
suspension. Renal elimination occurs after drug degradation into peptides and 
amino acids in the liver. The drug half-life was estimated at 25.5 days, being 
the potential predictors of poor response to therapy: albumin <3.2 g/dl and 
weight > 120 kg [15].
The currently recommended dosage is 300 mg vedolizumab with intravenous 
administration at weeks 0, 2, and 6 and then every 8 weeks. The interval can be 
shortened to every 4 weeks when the patient’s response is not satisfactory [15].
Studies showed no difference in serious adverse events resulting in death, 
life-threatening conditions, hospitalization, or disability, comparing vedoli-
zumab and placebo [14]. However, possible adverse events can occur such as 
nasopharyngitis, headache, arthralgia, and other less uncommon events. Among 
the contraindications, we can highlight the presence of active infections, such as 
tuberculosis, sepsis, cytomegalovirus, listerioses, and opportunistic infections 
such as PML [16, 17].
There are no controlled studies of vedolizumab during pregnancy and breast-
feeding, and current data are based on observational cases. FDA classified this drug 
as category B, being safe for use in pregnancy. During breastfeeding, caution is 
required because it is not known if the medication is transferred to the newborn [4].
In 2013, the randomized, double-blind, placebo-controlled phase 3, GEMINI I 
study showed the efficacy of vedolizumab in induction and maintenance of remis-
sion in patients with UC. For induction, a 300 mg-day intravenous dose repeated 
at 15 days was used. For maintenance, both groups received the medication after 
4 or 8 weeks; therapeutic serum levels were obtained with 95% saturation of the 
α4β7 receptor and proven clinical remission for 52 weeks. The intestinal selectivity 
of vedolizumab gives the drug greater safety, especially in countries with a marked 
presence of mycobacteria. No cases of PML were documented during the GEMINI I 
study [14].
Also, in 2013, the GEMINI II placebo-controlled, randomized, double-blind, 
phase 3 study evaluated induction and maintenance remission in patients with 
moderately to severely active CD for 4 years in 39 countries. The study analyzed 
patients aged 18–80 years, diagnosed for at least 3 years, with active CD. Compared 
to placebo, patients treated with vedolizumab had better response in both induction 
and remission maintenance at week 52. The rates were discrete and may be justified 
by patient selection bias, since a significant part of the group had severe disease, 
difficult to control and refractory to anti-TNF treatment [18].
Of the 1434 patients who used vedolizumab for 52 weeks evaluated in the 
GEMINI I and GEMINI II studies, 56 (4%) had anti-drug antibodies, of which 
only 9 (0.6%) had persistent positivity after two or more consecutive dosages. 
Immunogenicity increases with exposure time reaching 10% at week 66. However, 
it is believed that the presence of antibodies in low to moderate-titer does not affect 
drug response, as therapeutic failure occurred in only nine patients and elevated 
antibody levels were maintained for a prolonged period [15].
In 2014, Sands et al. (GEMINI III) evaluated the response of vedolizumab in 
patients with previous anti-TNF treatment. The study showed an advantage of 
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anti-integrin when compared to placebo only after 10 weeks, concluding that in 
patients who fail anti-TNF treatment, longer time is required to achieve clinical 
remission with vedolizumab [16].
The VARSITY study presented in 2019 was the first study that compared two 
biological drugs (vedolizumab and adalimumab). The randomized, double-blind 
phase 3 study evaluated clinical and endoscopic response at week 52 in patients with 
moderate-to-severe active UC treated with standard drug doses. Vedolizumab was 
more effective in inducing clinical remission and mucosal healing. There was no 
statistically significant difference between the drugs when the outcome evaluated 
was steroid-free remission. Both drugs were safe and well tolerated for treatment of 
moderate-to-severe UC [19].
No studies compared the efficacy of different biological agents in patients with CD.
2.2 Anti-interleukin 12/23p40
IBD presents a large infiltration of leukocytes, especially T lymphocytes. 
When activated, these cells produce a high concentration of cytokines that have 
an important role in the inflammatory process of the disease [20]. However, there 
seems to be a distinction in the profile of cytokines produced in CD and UC. While 
in CD there is a predominant synthesis of type 1 helper T-cell (Th1) cytokines, such 
as interferon-γ (IFN-γ) and TNF-α; in UC, Th2 cytokines, such as interleukin-5 and 
interleukin-13, are more relevant [20, 21].
CD mucosa has an increased production of interleukin-12 (IL-12), a pro-
inflammatory cytokine that induces IFN-γ production and promotes Th1 cell 
differentiation [22, 23]. IL-12 is a heterodimeric cytokine produced by macro-
phages, monocytes, and dendritic cells, with two covalently linked subunits: p40 
and p35 [23].
The IL-12p40 subunit can be combined with another cytokine, derived of IL-6 
subfamily structures, the p19 protein, to form the p19p40 complex, also nowed like 
interleukin-23 cytokine (IL-23) [24]. The natural function of IL-23 is to coordinate 
inflammatory responses within peripheral tissues. However, unregulated expression of 
IL-23 may promote detrimental immune pathology at these sites [25]. In IBD, IL-23 may 
play the role of initiating and perpetuating innate T cell-mediated intestinal inflamma-
tion [26], thus leaving the place to IL-12/IFN-γ/T-cell pathway in the late phase [20].
A systematic review published by MacDonald et al. evaluated the use of 
ustekinumab (CNTO 1275) and briakinumab (ABT-874), monoclonal anti-
bodies that target the standard p40 subunit of the cytokines IL-12 and IL-23 
(IL-12/23p40), in patients with CD [27]. In this review two studies that compared 
briakinumab to placebo and four studies that compared ustekinumab to placebo 
were analyzed.
In 2004, Mannon et al. investigated two different doses of briakinumab. This 
was a multisite, randomized, double-blind, placebo-controlled study where 79 CD 
patients received 1 or 3 mg of anti-IL-12p40 monoclonal antibody subcutaneous 
injections versus placebo. The results showed that the use of anti-IL-12p40 might 
induce clinical responses and remissions in patients with active CD, with responses 
in 75% of CD patients compared with 25% in the placebo group. These results were 
associated with decreases in Th1-mediated inflammatory cytokines (IFN-γ and 
TNF-α) at the site of disease. There were no significant differences in the rate of 
adverse effects between placebo and anti-IL-12, except a higher rate of local reac-
tions at injection sites in the former group [28].
The other study testing the use of briakinumab was published in 2015 and 
evaluated the efficacy and safety of this drug [29]. This was a phase 2b, multicenter, 
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double-blind, parallel group study, conducted with 246 patients with moderate-
to-severe CD stratified by prior TNF-α antagonist use and response to anti-TNF-α 
therapy, who were randomly given placebo and 200, 400, or 700 mg briakinumab 
over the period of 0, 4, and 8 weeks. On week 12, patients who got clinical response 
in the placebo or 400-mg induction groups proceeded to the maintenance phase 
with the same protocol. Those who responded clinically with 700 mg were random-
ized to receive placebo and 200 or 700 mg briakinumab at weeks 12, 16, and 20 
during the maintenance phase. Patients in remission stopped receiving the study 
drug at week 24. During the induction and maintenance phase of this study, bria-
kinumab was well tolerated and had a safety profile similar to placebo. However, the 
authors pointed out that infusion reactions were observed in a higher percentage of 
patients treated with briakinumab than placebo during the induction phase (up to 
week 12). After week 12, adverse events and severe reactions occurred at a higher 
rate, mainly due to the increase in serious infusion reactions. The sponsor stopped 
the study during the open-label phase due to poor induction of remission results.
These investigations did not find severe side effects comparing briakinumab and 
placebo. However, there were common reactions to the site of injection and some 
secondary infections produced by briakinumab therapy. Due to these results, the 
production of briakinumab was interrupted [27].
Sandborn et al. conducted a phase IIa study of ustekinumab comparing clini-
cal effects to placebo [30]. They made a double-blind, crossover design with 
104 patients with moderate-to-severe CD, including both TNF-α antagonist 
naive patients and those who had previously failed one or more of these agents. 
These patients were divided into four groups: two groups received subcutaneous 
treatment doses, of which one group received placebo at weeks 0–3 and then 90 mg 
ustekinumab at weeks 8–11, while the other group received 90 mg ustekinumab 
at weeks 0–3 and then placebo at weeks 8–11. The other two groups followed 
the same weekly protocol, but the pathway was intravenous, and the dose was 
4.5 mg/kg ustekinumab. Furthermore, a sub study like open-label trial evaluated 
the effects of four weekly subcutaneous injections of 90 mg or one intravenous 
infusion of 4.5 mg/kg ustekinumab in 27 patients who were primary or second-
ary nonresponders to infliximab, but it was not placebo-controlled. They showed 
that ustekinumab induced a clinical response in CD patients, who were previously 
treated infliximab, with the best effect in weeks 4–6 [30].
In 2012, Sandborn et al. published another study that evaluated ustekinumab 
therapy in patients with moderate-to-severe CD which was resistant to anti-TNF-α. 
This was a double-blind, placebo-controlled phase 2b trial with 526 patients who 
were randomized to receive intravenous ustekinumab (1, 3, or 6 mg/kg) or placebo 
at week 0. After 6 weeks, the clinical response was measured, and 145 patients who 
responded to ustekinumab were randomized to receive subcutaneous injections 
of ustekinumab (90 mg) or placebo at weeks 8 and 16 in the maintenance phase. 
Patients who used ustekinumab as an induction therapy had a higher response 
than the placebo group but did not differ in remission. These patients, during the 
maintenance phase with ustekinumab administration, had a significant increase in 
response and remission rates when compared to placebo. It is noteworthy that some 
serious infections occurred during the study, which affected 7 patients (6 receiv-
ing ustekinumab) in the induction phase and 11 (4 receiving ustekinumab) in the 
maintenance phase [31].
According to MacDonald et al., strong evidence indicates that ustekinumab 
is efficient for remission induction and that it improves symptoms in patients 
with moderate-to-severe CD. Moderate- to high-quality evidence implies that the 
optimal dose of ustekinumab is 6 mg/kg [27].
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In addition to the improvement in patients’ clinical condition and symptomatol-
ogy, positive responses were also observed in histological examinations of patients 
who used maintenance therapy with ustekinumab every 8 weeks [32]. When 
analyzing histological data from participants in phase 3 induction and maintenance 
studies, significant histological improvement was observed in patients receiving 
ustekinumab compared to placebo [32].
Indeed, in 2016, with phase III UNITI trial program’s positive results [33], the US 
Food and Drug Administration (FDA) approved ustekinumab for the treatment of 
moderate-to-severe CD [34]. Although there is no increased risk of serious adverse 
events, further studies are needed to assess the long-term benefit of their use in 
patients with CD [27].
Recently a study was published evaluating the use of ustekinumab to treat 
patients with moderate-to-severe active UC who do not respond well or were unable 
to tolerate conventional treatment or biological therapies [35]. It was a randomized, 
double-blind, placebo-controlled phase 3 study. Patients receiving a single intrave-
nous ustekinumab dose of 130 mg or 6 mg/kg body weight (320 and 322 patients 
respectively) achieved clinical remission, endoscopic healing, clinical response, and 
mucosal healing at week 8, significantly better than placebo. It has been shown to 
be effective not only for the treatment of CD but also for the induction and mainte-
nance of remission in patients with moderate-to-severe UC [35].
Serious infections were the most common side effects in the ustekinumab stud-
ies [27]. The therapeutic target of this drug is the p40 subunit, and it is not selective 
for IL-12 or IL-23. IL-12 is known to mediate protective systemic antimicrobial 
immunity, so this immune suppression may be responsible for these secondary 
opportunistic infections [23].
Studies support the specific blockade of IL-23, for its blockade may be as effec-
tive as the blockade of both cytokines but may result in fewer infectious problems 
[26]. A recently published review study evaluated the use of two drugs as a 
specific antagonist of the p19 subunit [34]. Risankizumab and brazikumab are the 
first anti-IL23p19 whose results were positive in randomized placebo-controlled 
phase II study to induction and maintenance therapy for moderate-to-severe 
CD patients. This review showed that both adverse events and serious adverse 
events did not differ between the treated groups and placebo. These results were 
observed in phase II studies with risankizumab and brazikumab, to treat not 
only IBD but also psoriasis. Based on symptomatic, endoscopic, and positive 
biomarker results, as well as treatment safety and efficacy during phase II trials, 
phase III studies are ongoing. These studies will help answer questions about the 
optimal dosage of drugs and their action at other levels of CD  involvement [34].
3. JAK inhibitors
Despite advances in the therapeutic arsenal of IBDs, significant numbers of 
patients do not achieve mucosal healing. Janus kinase (JAK) inhibitors already used 
in oncological, rheumatological, and dermatological disease treatment are being 
studied as a new therapeutic resource against IBDs.
Many cytokines involved in IBD act on the JAK/signal transducer and activa-
tor of transcription (STAT) cell signaling pathway, generating cellular responses 
through gene expression [36]. By binding to specific membrane receptors, cyto-
kines activate JAK, which catalyzes the phosphorylation of the complex enabling 
STAT binding [37]. After phosphorylation, STATs dimerize, leave the receptor, and 
go to the cell nucleus to activate the transcription of the target gene [38].
7Anti-Integrins, Anti-Interleukin 12/23p40, and JAK Inhibitors for the Inflammatory Bowel…
DOI: http://dx.doi.org/10.5772/intechopen.90536
Some JAKs, like JAK1, JAK2, and JAK3, play an important role in the growth, dif-
ferentiation, and survival of immune system cells in general. Unlike the others, JAK3 
is present in hematopoietic cells, acting mediated signaling pathways by IL-2, IL-4, 
IL-7, IL-9, IL-15, and IL-21 [38]. According to Lovato et al., patients with CD have an 
overactivation of STAT3 and STAT4 in intestinal T cells [39]. Therefore, despite the 
importance in diverse cellular activities, changes in the JAK/STAT signaling path-
ways have been related to various immune disorders [38].
JAK inhibitors have been developed and are under clinical investigation to assess 
their ability to attenuate the inflammation process in UC [40]. Tofacitinib (CP-
690,550), a first-class JAK360 inhibitor, works by inhibiting JAK1/JAK3 and has a 
lower side effect on JAK2 and TYK2 [41]. This JAK inhibitor was tested in clinical 
trials to verify its potential treatment for some immune system disorders, including 
CD and UC [42].
To test the efficacy of tofacitinib in UC, a double-blind, placebo-controlled, 
phase 2 trial study was conducted [40]. Patients with moderately to severely active 
UC (n = 194) randomly received placebo or tofacitinib at a dose of 0.5, 3, 10, or 
15 mg twice daily for 8 weeks. Significant clinical remission (Mayo score ≤ 2, 
with no subscore >1) at 8 weeks occurred in patients who received 10 mg (48%, 
p < 0.001) and 15 mg (41%, p < 0.001), compared with 10% in placebo group. 
Endoscopic remission at 8 weeks occurred in patients receiving 10 mg (30%, 
p < 0.001) and 15 mg (27%, p < 0.001), compared with 2% in placebo group.
OCTAVE Induction 1 and 2 were phase 3, randomized, double-blind, placebo-
controlled studies in patients with moderately to severely active UC [43]. Patients 
randomly received tofacitinib (10 mg twice daily) or placebo for 8 weeks. In 
the OCTAVE Induction 1 (n = 598 patients), remission occurred in 18.5% of the 
patients in tofacitinib group and in 8.2% in placebo group (p = 0.007). In OCTAVE 
Induction 2 (n = 541 patients), remission occurred in 16.6 versus 3.6%, respectively 
(p < 0.001). According to the results, tofacitinib use showed remission induc-
tion after 8 weeks of use in patients with moderate-to-severe UC compared with 
placebo [43].
In OCTAVE sustain study, the rate of maintenance of clinical remission was 
evaluated. The patients with clinical response to induction therapy in OCTAVE 
Induction 1 and 2 were followed for 52 weeks. The patients were randomized 
into three groups (placebo, 10 mg and 5 mg, 2 times daily). The clinical remis-
sion at 52 weeks occurred in 34.3% (n = 68/ 198) of patients taking 5 mg; 40.6% 
(n = 80/197) with 10 mg; and 11.1% (n = 22/198) in the placebo group. The 
mucosal healing rate at 52 weeks was 37.4% (n = 74/198) in patients on 5 mg; 
45.7% (n = 90/197) in those who used 10 mg; and 13.1% in the placebo group 
(26/198) [43].
In patients with CD, initial studies with JAK inhibitors have shown unsatisfac-
tory results in inducing clinical and endoscopic remission of the disease. In a, 
multicenter, randomized, double-blind, placebo-controlled phase 2 study, patients 
with severe CD (CDAI between 220 and 450) were randomized to receive placebo 
or 1 mg, 5 mg, and 15 mg tofacitinib, twice daily for 4 weeks. Clinical response 
and remission were similar between both groups. However, this outcome could be 
associated with a selection bias in the control group [44].
Another multicenter phase IIb, randomized, double-blind, placebo-controlled 
study evaluated patients with moderate-to-severe CD. Patients were assigned 
randomly to receive placebo or tofacitinib 5 or 10 mg twice daily for 8 and 26 weeks. 
The rates of clinical response (decrease in CDAI ≥100 from baseline) and clinical 
remission (CDAI <150) at week 8 and 26 were not significantly different from the 
placebo [45].
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In 2018, tofacitinib was the first JAK inhibitor to be approved by the US FDA and 
the European Medicines Agency’s Committee for Medicinal Products for Human 
Use (CHMP) to treat moderate-to-severe active UC. According to EMA it should be 
used in patients who have tried conventional therapy or biological agents and failed 
or did not progress positively.
There is another small molecule, still in the testing phase, which selectively acts 
on important specific pathways in UC and CD, thus limiting some of the side effects 
such as bacterial and viral infections [41].
Indeed, tofacitinib therapy in rheumatoid arthritis showed an increased risk 
of infection, including herpes zoster [46]. Herpes zoster infection, among others, 
was also observed in the OCTAVE study comparing the use of 10 mg tofacitinib 
with placebo [43]. Vaccination against herpes zoster is indicated 3–4 weeks before 
starting tofacitinib treatment as a preventive strategy [47].
The other most common adverse effects of using JAK inhibitors are influenza, 
rhinopharyngitis, arthralgia, and headache. Studies in patients with rheumatologic 
diseases and psoriasis have not shown increased cardiovascular risk in patients 
treated with tofacitinib [43], although there may be an increase in HDL and LDL 
cholesterol serum levels [40].
In a cohort analysis, including OCTAVE I and II and Sustain, with UC patients 
exposed to tofacitinib, 25 cases of pregnancy occurred, but no definitive conclu-
sions about maternal and fetal risks, due to methodological limitations (absence of 
control group, retrospective study, and small number of cases) [48]. Further stud-
ies are needed to assess medication safety in pregnant women. It is not currently 
approved for pregnant and breastfeeding women [47, 48]. In addition, information 
provided by the manufacturer itself showed preclinical trials with rabbits and rats 
that showed a risk of fetal malformations with the use of tofacitinib but at doses 10 
times higher than recommended for humans [Pfizer Inc. Xeljanz prescribes infor-
mation, http://labeling.pfizer.com/ShowLabeling.aspx?id=959 (2014, accessed July 
13, 2019)] [47].
Vermeire et al. evaluated the efficacy of filgotinib, a kind of selective JAK1 
inhibitor [49]. This search was a randomized, double-blinded, placebo-con-
trolled phase II FITZROY study, with CD patients with moderate-to-severe activ-
ity. The patients received 200 mg filgotinib once daily or placebo for 10 weeks. 
As a result, the number of patients who received the drug and went into remis-
sion was much larger than that of those who received placebo after 10 weeks of 
treatment. This study showed the first evidence for potential clinical efficacy and 
safety of a selective JAK1 inhibitor for the treatment of active CD [49]. Filgotinib 
might represent a new oral treatment to induce remission in patients with CD, 
but a phase III study will still be necessary [42]. According to Soendergaard 
et al., a combined phase IIb/III randomized, placebo-controlled study with 
filgotinib for the treatment of moderate-to-severe UC (the SELECTION1 study) 
is ongoing.
4. Conclusion
Inflammatory bowel diseases have very complex pathophysiological mecha-
nisms, which makes treatment difficult. Advances in research presented here show 
new possibilities for alternative treatments, some already approved by the FDA 
(ustekinumab and tofacitinib) and others still under investigation.
The study of these alternative biological therapies is very important to help 
treat severe CD and UC patients with previous therapeutic failures, who no longer 
respond to or have not adapted to conventional treatments.
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